Cookies are used to help provide a better web service to patients and others.
Uses include: remembering products you add to our cart, understanding what people need and ensuring our website works properly.
An easy to understand guide on how alectinib works.
A closer look at the function and efficicacy of niraparib as a maintenace treatment.
Tagrisso (osimertinib) has been approved in Europe to treat Epidermal Growth Factor Receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as a first-line treatment.
New clinical results show that Durvalumab improved survival (versus a placebo) in patients with non–small cell lung cancer.
A new preventive migraine treatment, Aimovig (erenumab-aooe), poses promising possibilities for some migraine sufferers.
There are a number of medicines available for melanoma patients. In this article we examine one newer medicine and discuss it's efficacy and use.
The European Medicines Agency has recently approved Niraparib (Zejula) for use in the European Union as a treatment for women struggling with a specific type of advanced ovarian cancer known as high-grade serous epithelial ovarian cancer, which includes cancers that affect the peritoneum and/or the fallopian tubes.
When a new medicine gets approved for use and for sale in a specific region, it’s usually given a brand name by the pharmaceutical company who discovered or developed it.
‘Unapproved medicines’, ‘compassionate use’, ‘early access drugs’..